NovaMed Pharmaceuticals

What NovaMed Pharmaceuticals does

NovaMed Pharmaceuticals is a China-centric specialty pharmaceutical company founded in 2005 with the stated goal of building China's first "virtual integrated" pharmaceutical group. Its founding team comprised former senior executives from multinational pharmaceutical companies, and it was originally capitalized by international venture capital and private investment (notably Atlas Venture, F-Prime, and Eight Roads Ventures, which funded disclosed rounds of $5M in 2007 and $13.8M in 2008). In early 2011, SciClone Pharmaceuticals Inc (founded 1992, headquartered in San Francisco) acquired NovaMed and merged the two entities into a unified company branded SciClone NovaMed, with combined China-based headcount exceeding 700 employees.

The company's product platform is centered on ZADAXIN (thymalfasin/thymosin alpha 1), an immunotherapy indicated for cancer and serious infectious diseases that has been marketed in China since 1996 and is described as one of the largest drug imports in the Chinese pharmaceutical market. The company states a "substantial international business and new therapy portfolio" beyond ZADAXIN, sourced via strategic alliances with European and Japanese partners. The stated operating scope spans the full commercial value chain: sales and marketing, registration, distribution, production, and R&D, executed through a "virtual integration" model rather than a single vertically integrated entity.

Commercially, NovaMed operates a direct-sales go-to-market with wholly-owned branch offices in nine Chinese cities (Beijing, Shanghai, Guangzhou, Hangzhou, Nanjing, Chongqing, Tianjin, Shenyang, Urumqi), targeting hospitals, physicians, and ultimately patients in oncology and serious infectious disease. Revenue is generated through unit sales of imported specialty pharmaceuticals (predominantly ZADAXIN), with no public pricing disclosure. Following the 2011 merger, the company is a subsidiary of SciClone Pharmaceuticals Inc (a privately held California corporation), with operational continuity maintained through the NovaMed China legal entity (诺凡麦医药贸易（上海）有限公司) and its regional branches.

Name

NovaMed Pharmaceuticals

Legal name

SciClone Pharmaceuticals Inc

Website

https://c1000018659.jobuy.com

Company type

Private

Founded year

2005

Operating status

Acquired

Headcount range

1–10 employees

Short description

NovaMed Pharmaceuticals is a China-focused specialty pharmaceutical company that imports and distributes Western-produced medications for cancer and serious infectious diseases, primarily ZADAXIN (thymalfasin), via a direct sales force across nine Chinese cities. It operates as a subsidiary of SciClone Pharmaceuticals following a 2011 merger.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Specialty pharmaceuticals
• Immunotherapy drugs
• Oncology medications
• Infectious disease treatment
• Pharmaceutical distribution

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations

Revenue model

1. Pharmaceutical Product Sales: Revenue generated through sales of specialty pharmaceutical products including ZADAXIN (thymalfasin) for cancer and infectious diseases, marketed and distributed directly through the company's sales force across China

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

NovaMed Pharmaceuticals is a China-focused specialty pharmaceutical company that sells ZADAXIN (thymalfasin/thymosin alpha 1), a Western-produced immunotherapy drug for the treatment of cancer and serious infectious diseases. The company manages full commercial functions including sales and marketing, regulatory registration, distribution, production, and R&D, supplying its products to healthcare providers across China.

Product overview

NovaMed Pharmaceuticals is a specialty pharmaceutical company focused on cancer and severe infectious diseases. Following its acquisition by SciClone Pharmaceuticals in 2011, the company operates as a unified entity offering ZADAXIN (thymalfasin/thymosin alpha 1) as its primary product. The company provides high-quality, Western-manufactured medications for deadly diseases, with完备的商业职能 including sales and marketing, registration, distribution, production, and R&D.

Differentiator

Problem solved

Functional benefit

Brands

• ZADAXIN: Thymalfasin (thymosin alpha 1) - main pharmaceutical product for cancer and infectious diseases, introduced in China since 1996

Products and services

• ZADAXIN (Thymalfasin / Thymosin Alpha 1) ZADAXIN is a thymosin alpha 1 immunotherapy drug used for treating cancer and infectious diseases. It has been marketed in China since 1996 and is positioned as one of the largest imported pharmaceutical products in the Chinese market, widely accepted by doctors and patients for its high quality and high safety profile. The drug is intended for healthcare providers and patients treating cancer and serious infectious diseases.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• SciClone PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2011In early 2011, SciClone Pharmaceuticals Inc acquired NovaMed Pharmaceuticals Inc. The two companies merged to form a unified company, combining SciClone's international presence with NovaMed's China-focused operations. This merger brought together SciClone's ZADAXIN product portfolio with NovaMed's local market expertise and sales network across China.
• European PartnersminorStrategic or Co-development PartnerStrategic alliance established with European partners as part of international business operations.
• Japanese PartnersminorStrategic or Co-development PartnerStrategic alliance established with Japanese partners as part of international business operations.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Innovent Biologics: China-based biologics company commercializing innovative oncology and immunology therapies through a domestic sales force. Comparable therapeutic focus and channel, though Innovent is developer-led rather than import-led.

Broad incumbents

• CSPC Pharmaceutical Group: Major Chinese pharmaceutical group with significant specialty and oncology drug franchises and an established China hospital channel. Comparable as a broader incumbent in the same therapeutic categories.
• Sino Biopharmaceutical: Large diversified Chinese pharma with oncology, hepatitis, and specialty franchises sold through a nationwide hospital sales force. Comparable as an incumbent Chinese pharma operating in overlapping disease areas.
• Shanghai Pharmaceuticals Holding: One of China's largest pharma groups combining drug manufacturing with distribution and hospital-channel sales. Comparable as a broad incumbent with both branded specialty products and China distribution scale.
• Jiangsu Hengrui Medicine: One of China's largest innovative pharma companies, with broad oncology and specialty care portfolios and a deep domestic sales network. Comparable as an incumbent Chinese specialty pharma competing in overlapping indications.

Direct peers

• SciClone Pharmaceuticals: SciClone is the US parent of NovaMed following the 2011 acquisition, sharing the ZADAXIN portfolio and the China specialty pharma commercialization platform. Most directly comparable given overlapping product, geographic focus, and commercial model.
• BeiGene: China-headquartered oncology-focused biopharma with a large China commercial footprint and global development capabilities. Comparable as a China-centric specialty oncology company competing for the same prescriber base.
• Zai Lab: US-listed, China-focused specialty biopharma commercializing imported innovative oncology and infectious disease drugs through a direct sales force. Closely comparable business model of bringing western-produced therapies to China.
• Hutchmed (HUTCHISON MediPharma): China-rooted oncology-focused specialty pharma with both in-house innovation and in-licensed international assets, commercialized through its own China commercial team. Comparable on therapeutic area and hybrid global-local model.
• 3Sbio: China-based specialty biopharmaceutical company with a portfolio of biologics in oncology and immunology, sold through a China-wide hospital-focused sales force. Comparable on therapeutic area, biologic modality, and specialty pharma GTM.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries9 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovaMed Pharmaceuticals